America First Investment Advisors LLC Buys 11,672 Shares of Abbott Laboratories (NYSE:ABT)

America First Investment Advisors LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 6.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 183,631 shares of the healthcare product maker’s stock after buying an additional 11,672 shares during the quarter. Abbott Laboratories comprises about 4.7% of America First Investment Advisors LLC’s portfolio, making the stock its 11th largest holding. America First Investment Advisors LLC’s holdings in Abbott Laboratories were worth $19,081,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ABT. Unique Wealth Strategies LLC bought a new position in shares of Abbott Laboratories during the second quarter worth approximately $28,000. Transcendent Capital Group LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $29,000. Richardson Financial Services Inc. acquired a new stake in Abbott Laboratories in the 4th quarter worth about $29,000. Redmont Wealth Advisors LLC bought a new stake in Abbott Laboratories in the 1st quarter valued at about $30,000. Finally, True Wealth Design LLC increased its holdings in shares of Abbott Laboratories by 1,677.8% during the fourth quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock worth $35,000 after purchasing an additional 302 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABT. Royal Bank of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Abbott Laboratories in a research report on Tuesday, June 4th. Edward Jones cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Evercore ISI reduced their price objective on shares of Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. The Goldman Sachs Group began coverage on shares of Abbott Laboratories in a report on Thursday, May 30th. They set a “buy” rating and a $121.00 price target for the company. Finally, Citigroup lifted their price objective on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $121.80.

Abbott Laboratories Stock Up 0.5 %

Shares of NYSE:ABT opened at $117.05 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.68. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64. The company has a market capitalization of $203.62 billion, a PE ratio of 36.46, a price-to-earnings-growth ratio of 2.83 and a beta of 0.72. The company has a fifty day moving average of $108.42 and a 200-day moving average of $108.63.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The firm had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.37 billion. During the same period last year, the firm posted $1.08 earnings per share. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post 4.66 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 15th. Stockholders of record on Monday, July 15th were issued a dividend of $0.55 per share. The ex-dividend date was Monday, July 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.88%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.